You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 21, 2024

Allergan Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Allergan

Drugs and US Patents for Allergan

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan AVAGE tazarotene CREAM;TOPICAL 021184-003 Sep 30, 2002 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up
Allergan SAPHRIS asenapine maleate TABLET;SUBLINGUAL 022117-002 Aug 13, 2009 AB RX Yes Yes 7,741,358*PED ⤷  Sign Up Y ⤷  Sign Up
Allergan KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-010 Jul 9, 2012 DISCN Yes No ⤷  Sign Up ⤷  Sign Up
Allergan SAPHRIS asenapine maleate TABLET;SUBLINGUAL 022117-001 Aug 13, 2009 AB RX Yes No 8,022,228*PED ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Allergan

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan DILACOR XR diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020092-002 May 29, 1992 5,422,123 ⤷  Sign Up
Allergan GELNIQUE 3% oxybutynin GEL, METERED;TRANSDERMAL 202513-001 Dec 7, 2011 7,198,801 ⤷  Sign Up
Allergan SAPHRIS asenapine maleate TABLET;SUBLINGUAL 022117-002 Aug 13, 2009 5,763,476*PED ⤷  Sign Up
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-002 Jun 13, 1997 5,914,334 ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ALLERGAN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 60 mg ➤ Subscribe 2009-03-02
➤ Subscribe Transdermal System Extended-re 3.9 mg/24 hrs ➤ Subscribe 2008-08-19
➤ Subscribe Ophthalmic Solution 0.30% ➤ Subscribe 2007-07-19
➤ Subscribe Tablets 2.5 mg, 5 mg, 10 mg, and 20 mg ➤ Subscribe 2011-12-19
➤ Subscribe Sublingual Tablets 2.5 mg ➤ Subscribe 2017-07-27
➤ Subscribe Capsules 4 mg and 8 mg ➤ Subscribe 2012-10-09
➤ Subscribe Ophthalmic Solution 0.05% ➤ Subscribe 2008-10-14
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2007-10-16
➤ Subscribe Sublingual Tablets 5 mg and 10 mg ➤ Subscribe 2013-08-13

Supplementary Protection Certificates for Allergan Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1214076 C01214076/01 Switzerland ⤷  Sign Up PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
2782584 301153 Netherlands ⤷  Sign Up PRODUCT NAME: COMPOSITION CONTAINING BOTH ESTRADIOL (17SS-ESTRADIOL), OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF (INCLUDING IN HEMIHYDRATE FORM), AND PROGESTERONE; NATIONAL REGISTRATION NO/DATE: RVG 125821 20210611; FIRST REGISTRATION: BE BE582231 20210406
0392059 SPC/GB02/046 United Kingdom ⤷  Sign Up PRODUCT NAME: MEMANTINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/219/001 20020515; UK EU/1/02/219/002 20020515; UK EU/1/02/219/003 20020515; UK EU/1/02/219/004 20020515; UK EU/1/02/219/005 20020515; UK EU/1/02/219/006 20020515
1480644 SPC/GB17/004 United Kingdom ⤷  Sign Up PRODUCT NAME: COMBINATION OF CEFTAZIDIME, OR A SALT THEREOF, AND AVIBACTAM, OR A SALT THEREOF; REGISTERED: UK EU/1/16/1109/001 20160628
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.